Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Jennifer A. Regan; Yun Cao; Melanie C. Dispenza; Shuo Ma; Leo I. Gordon; Adam M. Petrich; Bruce S. Bochner

doi:10.1016/j.jaci.2017.03.013

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Jennifer A. Regan, Yun Cao, Melanie C. Dispenza, Shuo Ma, Leo I. Gordon, Adam M. Petrich, Bruce S. Bochner

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	875-879.e1
Journal	Journal of Allergy and Clinical Immunology
Volume	140
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2017.03.013
State	Published - Sep 2017

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2017.03.013

Cite this

Regan, J. A., Cao, Y., Dispenza, M. C., Ma, S., Gordon, L. I., Petrich, A. M., & Bochner, B. S. (2017). Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. Journal of Allergy and Clinical Immunology, 140(3), 875-879.e1. https://doi.org/10.1016/j.jaci.2017.03.013

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. / Regan, Jennifer A.; Cao, Yun; Dispenza, Melanie C.; Ma, Shuo; Gordon, Leo I.; Petrich, Adam M.; Bochner, Bruce S.

In: Journal of Allergy and Clinical Immunology, Vol. 140, No. 3, 09.2017, p. 875-879.e1.

Research output: Contribution to journal › Article › peer-review

Regan, JA, Cao, Y, Dispenza, MC, Ma, S, Gordon, LI, Petrich, AM & Bochner, BS 2017, 'Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity', Journal of Allergy and Clinical Immunology, vol. 140, no. 3, pp. 875-879.e1. https://doi.org/10.1016/j.jaci.2017.03.013

Regan, Jennifer A. ; Cao, Yun ; Dispenza, Melanie C. ; Ma, Shuo ; Gordon, Leo I. ; Petrich, Adam M. ; Bochner, Bruce S. / Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. In: Journal of Allergy and Clinical Immunology. 2017 ; Vol. 140, No. 3. pp. 875-879.e1.

@article{609f4a8bfccf440b8098394cf968f7af,

title = "Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity",

author = "Regan, {Jennifer A.} and Yun Cao and Dispenza, {Melanie C.} and Shuo Ma and Gordon, {Leo I.} and Petrich, {Adam M.} and Bochner, {Bruce S.}",

year = "2017",

month = sep,

doi = "10.1016/j.jaci.2017.03.013",

language = "English (US)",

volume = "140",

pages = "875--879.e1",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

AU - Regan, Jennifer A.

AU - Cao, Yun

AU - Dispenza, Melanie C.

AU - Ma, Shuo

AU - Gordon, Leo I.

AU - Petrich, Adam M.

AU - Bochner, Bruce S.

PY - 2017/9

Y1 - 2017/9

UR - http://www.scopus.com/inward/record.url?scp=85018674480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018674480&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2017.03.013

DO - 10.1016/j.jaci.2017.03.013

M3 - Article

C2 - 28389390

AN - SCOPUS:85018674480

VL - 140

SP - 875-879.e1

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -